The Aroon Indicator for NRXP entered a downward trend on October 21, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 298 similar instances where the Aroon Indicator formed such a pattern. In 290 of the 298 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for NRXP turned negative on September 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 33 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NRXP's RSI Indicator exited the oversold zone, 30 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 66 cases where NRXP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
NRXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NRXP's P/B Ratio (-669.811) is very low in comparison to the industry average of (2.988). P/E Ratio (-5.157) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (29.851) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. NRXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The RSI Indicator for TVRD moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 28 of the 31 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for TVRD just turned positive on October 15, 2026. Looking at past instances where TVRD's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
Following a +5.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where TVRD advanced for three days, in 189 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
TVRD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TVRD as a result. In 67 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TVRD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TVRD entered a downward trend on September 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.623) is normal, around the industry mean (2.988). P/E Ratio (-0.355) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. TVRD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TVRD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NRXP | TVRD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 64 | 60 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 1 Undervalued | 61 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 99 | |
PRICE GROWTH RATING 1..100 | 80 | 94 | |
P/E GROWTH RATING 1..100 | 14 | 8 | |
SEASONALITY SCORE 1..100 | 50 | 46 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NRXP's Valuation (1) in the null industry is somewhat better than the same rating for TVRD (61). This means that NRXP’s stock grew somewhat faster than TVRD’s over the last 12 months.
NRXP's Profit vs Risk Rating (100) in the null industry is in the same range as TVRD (100). This means that NRXP’s stock grew similarly to TVRD’s over the last 12 months.
TVRD's SMR Rating (99) in the null industry is in the same range as NRXP (100). This means that TVRD’s stock grew similarly to NRXP’s over the last 12 months.
NRXP's Price Growth Rating (80) in the null industry is in the same range as TVRD (94). This means that NRXP’s stock grew similarly to TVRD’s over the last 12 months.
TVRD's P/E Growth Rating (8) in the null industry is in the same range as NRXP (14). This means that TVRD’s stock grew similarly to NRXP’s over the last 12 months.
| NRXP | TVRD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 73% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 71% | 2 days ago 77% |
| Momentum ODDS (%) | N/A | 2 days ago 82% |
| MACD ODDS (%) | 7 days ago 87% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 87% |
| Advances ODDS (%) | N/A | 2 days ago 82% |
| Declines ODDS (%) | 9 days ago 89% | 4 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 86% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NRXP’s FA Score shows that 2 FA rating(s) are green while TVRD’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NRXP’s TA Score shows that 3 TA indicator(s) are bullish while TVRD’s TA Score has 5 bullish TA indicator(s).
NRXP (@Biotechnology) experienced а +1.54% price change this week, while TVRD (@Biotechnology) price change was +2.00% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
NRXP is expected to report earnings on Nov 13, 2026.
TVRD is expected to report earnings on Nov 12, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, TVRD has been loosely correlated with TOVX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if TVRD jumps, then TOVX could also see price increases.
| Ticker / NAME | Correlation To TVRD | 1D Price Change % | ||
|---|---|---|---|---|
| TVRD | 100% | +2.82% | ||
| TOVX - TVRD | 41% Loosely correlated | -5.48% | ||
| NIKI - TVRD | 27% Poorly correlated | -7.88% | ||
| NRXP - TVRD | 27% Poorly correlated | +0.38% | ||
| VSTM - TVRD | 27% Poorly correlated | -1.39% | ||
| JSPR - TVRD | 26% Poorly correlated | +0.88% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SMCX | 9.74 | 1.56 | +19.07% |
| Defiance Daily Target 2X Long SMCI ETF (SMCX) | |||
| ARKG | 49.85 | 1.20 | +2.47% |
| ARK Genomic Revolution ETF (ARKG) | |||
| ZMUN | 49.83 | 0.03 | +0.07% |
| F/m Ultrashort Tax-Free Municipal ETF (ZMUN) | |||
| EAD | 5.95 | N/A | N/A |
| Allspring Income Opportunities Fund | |||
| LQDM | 23.05 | -0.01 | -0.02% |
| Amplify LQD Investment Grade 12% Target Income ETF (LQDM) | |||